Multicentre phase II pharmacological evaluation of rhizoxin
1996

Evaluation of Rhizoxin in Cancer Treatment

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): HL McLeod, LS Murray, J Wanders, A Setanoians, MA Graham, N Pavlidis, B Heinrich, WW ten Bokkel Huinink, DJTh Wagener, S Aamdal, J Verweij

Primary Institution: University of Glasgow

Hypothesis

Does rhizoxin demonstrate pharmacological efficacy in patients with various types of cancer?

Conclusion

Rhizoxin is rapidly eliminated from the body, and higher plasma concentrations are associated with better treatment responses in some patients.

Supporting Evidence

  • Rhizoxin showed preclinical anti-tumor activity against various human tumor cell lines.
  • Patients with higher rhizoxin plasma concentrations had better treatment responses.
  • Pharmacokinetic studies indicated rapid elimination of rhizoxin from the body.

Takeaway

Rhizoxin is a medicine that helps fight cancer, but it leaves the body quickly, and some patients respond better to it than others.

Methodology

Patients received rhizoxin intravenously, and blood samples were taken to analyze drug levels and effects.

Potential Biases

Potential biases due to the non-mandatory nature of pharmacological study participation.

Limitations

The study had a small sample size and variability in patient responses, which may affect the reliability of the results.

Participant Demographics

Patients with melanoma, breast, head and neck, and non-small-cell lung cancers from various European countries.

Statistical Information

P-Value

0.03

Confidence Interval

95% CI -16 to -264

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication